CN101688195A - 制备重组人凝血酶’644的方法 - Google Patents
制备重组人凝血酶’644的方法 Download PDFInfo
- Publication number
- CN101688195A CN101688195A CN200880023664A CN200880023664A CN101688195A CN 101688195 A CN101688195 A CN 101688195A CN 200880023664 A CN200880023664 A CN 200880023664A CN 200880023664 A CN200880023664 A CN 200880023664A CN 101688195 A CN101688195 A CN 101688195A
- Authority
- CN
- China
- Prior art keywords
- ecarin
- reorganization
- thrombogen
- zymoplasm
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010015680 recombinant human thrombin Proteins 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 108010085662 ecarin Proteins 0.000 claims abstract description 86
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 16
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 16
- 229940039716 prothrombin Drugs 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 50
- 230000008521 reorganization Effects 0.000 claims description 45
- 108010064129 Thrombogen Proteins 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 238000006473 carboxylation reaction Methods 0.000 claims description 19
- 230000021523 carboxylation Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 238000005215 recombination Methods 0.000 claims description 14
- 230000006798 recombination Effects 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 102000057593 human F8 Human genes 0.000 claims description 3
- 229940047431 recombinate Drugs 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 108010013113 glutamyl carboxylase Proteins 0.000 description 14
- 102100038182 Vitamin K-dependent gamma-carboxylase Human genes 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 241000237942 Conidae Species 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960003766 thrombin (human) Drugs 0.000 description 5
- 241001135756 Alphaproteobacteria Species 0.000 description 4
- 241000283323 Delphinapterus leucas Species 0.000 description 4
- 241000255601 Drosophila melanogaster Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000237852 Mollusca Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000003998 snake venom Substances 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006251 gamma-carboxylation Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 108010011227 meizothrombin Proteins 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 238000003153 stable transfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 2
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 241000256182 Anopheles gambiae Species 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 241000588879 Chromobacterium violaceum Species 0.000 description 2
- 241000237974 Conus textile Species 0.000 description 2
- 241000168726 Dictyostelium discoideum Species 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000192128 Gammaproteobacteria Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 241000589929 Leptospira interrogans Species 0.000 description 2
- 241000209510 Liliopsida Species 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000251752 Myxine glutinosa Species 0.000 description 2
- 241000276398 Opsanus tau Species 0.000 description 2
- 241000282515 Papio hamadryas Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010039286 S 2238 Proteins 0.000 description 2
- 244000082988 Secale cereale Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 241000589196 Sinorhizobium meliloti Species 0.000 description 2
- 241000187432 Streptomyces coelicolor Species 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000005844 autocatalytic reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000011902 gastrointestinal surgery Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 108010059642 isinglass Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000031915 positive regulation of coagulation Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007631 vascular surgery Methods 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WPVINHLVHHPBMK-ULQDDVLXSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]-1-[(2s)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCN1C(=O)[C@@H]1CCC(=O)N1 WPVINHLVHHPBMK-ULQDDVLXSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589173 Bradyrhizobium Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000195585 Chlamydomonas Species 0.000 description 1
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 1
- 241001638933 Cochlicella barbara Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000018683 Conus episcopatus Species 0.000 description 1
- 241001495101 Conus imperialis Species 0.000 description 1
- 241000032205 Conus omaria Species 0.000 description 1
- 241000288030 Coturnix coturnix Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000122860 Echis carinatus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- -1 Hemaseel Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000239220 Limulus polyphemus Species 0.000 description 1
- 241000970829 Mesorhizobium Species 0.000 description 1
- 240000005272 Mollugo verticillata Species 0.000 description 1
- 235000009382 Mollugo verticillata Nutrition 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 241001521797 Scorpaena notata Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209147 Triticum urartu Species 0.000 description 1
- 241000520892 Xanthomonas axonopodis Species 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000747 designer drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940077255 thrombin-jmi Drugs 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
蛋白 | CDNAEMBLACC# | 剪接变体(蛋白) | 突变 | GENEEMBLACC# |
谷氨酸-γ-羧化酶 | BC013979 | 2;BC013979;AF253530 | 1SNP(EMBL#U65896);2SNPs(OMIM#137167) | U65896 |
凝血酶原 | V00595 | 1;V00595 | 约100SNP′s(EMBL#AF478696) | AF478696 |
种 | 数据库登记号#/ID |
智人(Homo sapiens)(人) | NM_000821.2HUMGLUCARBHUMHGCABC004422HSU65896AF253530.1 |
Papio hamadryas(红狒狒) | AC116665.1 |
白鲸(Delphinapterus leucas)(白鲸) | AF278713 |
牛(Bos taurus)(牛) | NM_174066.2BOVCARBOXGBOVBGCA |
绵羊(Ovis aries)(家绵羊) | AF312035 |
褐鼠(Rattus norvegicus)(褐鼠) | NM_031756.1AF065387 |
小家鼠(Mus musculus)(小鼠) | NM_019802.1AF087938 |
蟾鱼(Opsanus tau)(硬骨鱼) | AF278714.1 |
织锦芋螺(Conus textile)(软体动物) | AY0044904.1 |
AF382823.2 | |
堂皇芋螺(Conus imperialis)(软体动物) | AF448234.1 |
Conus episcopatus(软体动物) | AF448233.1 |
Conus omaria(软体动物) | AF448235.1 |
黑腹果蝇(Drosophila melanogaster)(果蝇) | NM_079161.2 |
冈比亚按蚊(Anopheles gambiae)(蚊) | XM_316389.1 |
黑麦(Secale cereale)(单子叶植物) | SCE314767 |
小麦(Triticum aestivum)(普通小麦) | AF280606.1 |
Triticum urartu(单子叶植物) | AY245579.1 |
大麦(Hordeum vulgare)(大麦) | BLYHORDCA |
问号钩端螺旋体(Leptospira interrogans)(螺旋体) | AE011514.1 |
天蓝色链霉菌(Streptomyces coelicolor)(高GC革兰氏阳性菌) | SCO939109SCO939124AF425987.1 |
变铅青链霉菌(Streptomyces lividans)(高GC革兰氏阳性菌) | SLU22894 |
Streptomyces viginiae(高GC革兰氏阳性菌) | SVSNBDE |
藤黄微球菌(Micrococcus luteus)(高GC革兰氏阳性菌) | MLSPCOPER |
雷氏衣藻(Chlamydomonas reinhardtii)(绿藻) | AF479588.1 |
盘基网柄菌(Dictyostelium discoideum)(粘菌) | AC115612.2 |
鹌鹑(Coturnix coturnix)(鸟类) | AF364329.1 |
慢生大豆根瘤菌(Bradyrhizobium.japonicum)(α-proteobacteria) | AP005937.1 |
类球红细菌(Rhodobacter sphaeroides)(α-proteobacteria) | RSY14197 |
苜蓿中华根瘤菌(Sinorhizobium meliloti)(α-proteobacteria) | RME603647AF119834 |
Mesorhizobium loti(α-proteobacteria) | AP003014.2 |
青紫色素杆菌(Chromobacterium violaceum)(β-proteobacteria) | AE016910.1AE016918.1 |
铜绿假单胞菌(Pseudomonas aeruginosa)(γ-proteobacteria) | AE004613.1AF165882 |
地毯草黄单胞菌(Xanthomonas axonopodis)(γ-proteobacteria) | AE011706.1 |
人疱疹病毒8 | KSU52064 |
KSU75698AF305694AF360120AF192756 |
实验ID | 培养方法&时间 | 存活细胞(百万细胞/mL) | 凝血酶原mg/L |
CC2LC(272-8) | 分批,238h | 5.9 | 281 |
CC2LD(272-8) | 分批,238h | 6.2 | 276 |
326-11B | 灌流,259h | 18 | 722 |
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94820707P | 2007-07-06 | 2007-07-06 | |
US60/948,207 | 2007-07-06 | ||
PCT/SE2008/050836 WO2009008821A1 (en) | 2007-07-06 | 2008-07-04 | Method for production of recombinant human thrombin `644 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101688195A true CN101688195A (zh) | 2010-03-31 |
CN101688195B CN101688195B (zh) | 2014-12-03 |
Family
ID=40228838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880023664.2A Expired - Fee Related CN101688195B (zh) | 2007-07-06 | 2008-07-04 | 制备重组人凝血酶‘644的方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US8206967B2 (zh) |
EP (1) | EP2179038B1 (zh) |
JP (1) | JP5661459B2 (zh) |
CN (1) | CN101688195B (zh) |
AU (1) | AU2008275828B2 (zh) |
BR (1) | BRPI0813743A2 (zh) |
CA (1) | CA2692656A1 (zh) |
WO (1) | WO2009008821A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107267492A (zh) * | 2017-07-10 | 2017-10-20 | 中山大学 | 一种尖吻蝮蛇凝血酶重组蛋白的表达方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
CN101094867B (zh) | 2004-10-19 | 2011-08-24 | 隆萨股份公司 | 用于固相肽合成的方法 |
KR20130140221A (ko) * | 2005-04-13 | 2013-12-23 | 아스트라제네카 아베 | 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포 |
US8206967B2 (en) * | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
CN102690803B (zh) * | 2011-03-24 | 2015-04-29 | 苏州泽璟生物制药有限公司 | 一种重组人凝血酶在动物细胞内的高效表达和生产方法 |
EP2556842A1 (en) | 2011-08-11 | 2013-02-13 | Bioftalmik, S.L. | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
WO2020229521A1 (en) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for inhibiting or reducing bacterial biofilms on a surface |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1551917A (zh) * | 2001-07-06 | 2004-12-01 | ���ŷ��˻�ѧ��Ѫ���Ʒ��о��� | 利用基因工程技术制备人凝血酶的方法 |
WO2005038019A1 (en) * | 2003-10-14 | 2005-04-28 | Astrazeneca Ab | Method for producing gamma-carboxylated proteins |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3043857A1 (de) * | 1980-11-21 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii |
US4599308A (en) * | 1981-10-06 | 1986-07-08 | Hamer Dean H | Protein from SV40 recombinants |
DE3584341D1 (de) * | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
WO1988003926A1 (en) | 1986-11-17 | 1988-06-02 | New England Medical Center | Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins |
US6224864B1 (en) * | 1986-12-03 | 2001-05-01 | Pharmacia & Upjohn Company | Antibiotic 10381A, and process for the preparation of anitbiotics 10381B |
EP0380508A4 (en) | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
CA1330302C (en) * | 1988-01-18 | 1994-06-21 | Miroslav Rybak | Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use |
JPH05508551A (ja) | 1990-07-23 | 1993-12-02 | ザイモジェネティクス,インコーポレイティド | ガンマーカルボキシラーゼおよび使用の方法 |
US5965789A (en) * | 1991-01-11 | 1999-10-12 | American Red Cross | Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals |
US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5219995A (en) | 1992-07-14 | 1993-06-15 | Alpha Therapeutic Corporation | Plasma fraction purification |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5639661A (en) * | 1994-03-23 | 1997-06-17 | The University Of Iowa Research Foundation | Genes and proteins for treating cystic fibrosis |
DE4430204A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung |
SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
JP2002500011A (ja) | 1997-12-24 | 2002-01-08 | イミュネックス・コーポレーション | V201dna及びポリペプチド |
US6413737B1 (en) * | 1999-07-09 | 2002-07-02 | Cohesion Technologies, Inc. | Ecarin prothrombin protease and methods |
AU6366100A (en) | 1999-07-23 | 2001-02-13 | Case Western Reserve University | Novel methods and reagents for the treatment of osteoarthritis |
WO2001096587A2 (en) | 2000-06-13 | 2001-12-20 | The Children's Hospital Of Philadelphia | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
US8202973B2 (en) | 2000-10-02 | 2012-06-19 | Novo Nordisk Health Care Ag | Method for the production of vitamin K-dependent proteins |
EP1405912B8 (en) | 2001-07-06 | 2012-10-24 | The Chemo-Sero-Therapeutic Research Institute | Genetically modified ecarin and process for producing the same |
CN1254273C (zh) | 2001-07-10 | 2006-05-03 | 财团法人化学及血清疗法研究所 | 药学上稳定的止血组合物 |
DK2380985T3 (en) | 2003-09-23 | 2014-03-17 | Univ North Carolina | Cells expressing the vitamin K epoxide reductase, as well as their use |
PT2189523E (pt) | 2003-10-14 | 2012-01-24 | Baxter Healthcare Sa | Polipéptido de reciclagem de epóxido de vitamina k, vkorc1, um alvo terapêutico de cumarina e seus derivados |
DE602004026759D1 (de) | 2003-10-24 | 2010-06-02 | Chemo Sero Therapeut Res Inst | Neue rekombinante tierzellen mit hoher proteinproduktion, verfahren zur konstruktion davon sowie verfahren zur massenproduktion von protein unter verwendung davon |
EP1831363A1 (en) | 2004-12-21 | 2007-09-12 | Novo Nordisk Health Care AG | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems |
KR20130140221A (ko) * | 2005-04-13 | 2013-12-23 | 아스트라제네카 아베 | 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포 |
CA2632794C (en) | 2005-12-02 | 2015-04-07 | Wake Forest University Health Sciences | Compositions and methods for increasing production of recombinant gamma-carboxylated proteins |
EP2385125A3 (en) * | 2005-12-21 | 2012-04-11 | Inspiration Biopharmaceuticals, Inc. | Method of producing biologically active vitamin K dependent proteins by recombinant methods |
US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
-
2008
- 2008-07-03 US US12/167,614 patent/US8206967B2/en not_active Expired - Fee Related
- 2008-07-04 WO PCT/SE2008/050836 patent/WO2009008821A1/en active Application Filing
- 2008-07-04 CN CN200880023664.2A patent/CN101688195B/zh not_active Expired - Fee Related
- 2008-07-04 JP JP2010514702A patent/JP5661459B2/ja not_active Expired - Fee Related
- 2008-07-04 AU AU2008275828A patent/AU2008275828B2/en not_active Ceased
- 2008-07-04 BR BRPI0813743-9A2A patent/BRPI0813743A2/pt not_active IP Right Cessation
- 2008-07-04 CA CA 2692656 patent/CA2692656A1/en not_active Abandoned
- 2008-07-04 EP EP08779414.5A patent/EP2179038B1/en not_active Not-in-force
-
2012
- 2012-06-15 US US13/524,689 patent/US20120258090A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1551917A (zh) * | 2001-07-06 | 2004-12-01 | ���ŷ��˻�ѧ��Ѫ���Ʒ��о��� | 利用基因工程技术制备人凝血酶的方法 |
WO2005038019A1 (en) * | 2003-10-14 | 2005-04-28 | Astrazeneca Ab | Method for producing gamma-carboxylated proteins |
CN1867669A (zh) * | 2003-10-14 | 2006-11-22 | 阿斯特拉曾尼卡有限公司 | 生产伽马-羧化的蛋白的方法 |
Non-Patent Citations (1)
Title |
---|
YONEMURA,H.等: "Preparation of recombinant alpha-thrombin:high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin", 《JOURNAL OF BIOCHEMISTRY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107267492A (zh) * | 2017-07-10 | 2017-10-20 | 中山大学 | 一种尖吻蝮蛇凝血酶重组蛋白的表达方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0813743A2 (pt) | 2014-10-07 |
US20120258090A1 (en) | 2012-10-11 |
JP5661459B2 (ja) | 2015-01-28 |
EP2179038B1 (en) | 2014-04-02 |
JP2010532661A (ja) | 2010-10-14 |
AU2008275828A1 (en) | 2009-01-15 |
WO2009008821A1 (en) | 2009-01-15 |
US8206967B2 (en) | 2012-06-26 |
CN101688195B (zh) | 2014-12-03 |
US20090047273A1 (en) | 2009-02-19 |
EP2179038A4 (en) | 2012-01-18 |
EP2179038A1 (en) | 2010-04-28 |
CA2692656A1 (en) | 2009-01-15 |
AU2008275828B2 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11965012B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
CN110117577B (zh) | 低毒单纯疱疹病毒系统及其构建方法和应用 | |
CN101688195A (zh) | 制备重组人凝血酶’644的方法 | |
KR101762970B1 (ko) | 면역 기반 보툴리눔 독소 혈청형 a 활성 검정에 유용한 세포 | |
KR101599062B1 (ko) | 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포 | |
KR101609894B1 (ko) | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 | |
KR101923847B1 (ko) | 면역 기반 재표적화된 엔도펩티다제 활성 검정 | |
JP2024083457A (ja) | レンチウイルスベクターのバイオ生産法 | |
KR20210049133A (ko) | 무혈청 배지에서 벡터 제조 | |
CN113444830A (zh) | 用于检测SARS-CoV-2冠状病毒的试剂盒及其专用引物和探针 | |
CN112778425B (zh) | 一种降低脱靶效应的rna基因编辑系统的制备方法 | |
CN112513072A (zh) | 慢病毒载体转化的t-rapa细胞在改善溶酶体贮积症中的应用 | |
CN114324864A (zh) | 一种水痘-带状疱疹病毒的IgM和IgG双检免疫层析试纸及应用 | |
CN111690687B (zh) | 促进骨骼肌发育的方法和应用 | |
CN114324878A (zh) | 一种荧光标记的水痘-带状疱疹病毒的免疫层析检测试纸及应用 | |
HK1142924A (zh) | 制备重组人凝血酶'644的方法 | |
CN113652412A (zh) | 一种制备限制性内切酶类产品的方法 | |
CN111333703A (zh) | 一种针对癌细胞基因损伤增殖信号通路的基因治疗药剂 | |
KR20230011965A (ko) | 외인성 단백질의 생산을 위한 변형된 사상균 | |
CN112080439A (zh) | 人源细胞凋亡调控蛋白Bcl-2在提高酿酒酵母橙花叔醇产量中的应用 | |
KR20140127692A (ko) | 재조합 단백질, 이를 코딩하는 재조합 유전자, 재조합 벡터, 및 이를 포함하는 약학조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142924 Country of ref document: HK |
|
CI01 | Publication of corrected invention patent application |
Correction item: Denomination of Invention Correct: Process for the preparation of recombinant human thrombin 644 False: Process for the preparation of recombinant human thrombin 644 Number: 13 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Denomination of Invention Correct: Process for the preparation of recombinant human thrombin 644 False: Process for the preparation of recombinant human thrombin 644 Number: 13 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTION NAME; FROM: METHOD FOR PRODUCTION OF RECOMBINANT HUMAN THROMBIN 644 TO: PRODUCTION OF RECOMBINANT HUMAN THROMBIN 644 METHOD FOR 644 |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 Termination date: 20150704 |
|
EXPY | Termination of patent right or utility model | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1142924 Country of ref document: HK |